Vimarsana
Biggest News Aggregation in the World

Multicenter Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multicenter Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multicenter Trial Today - Breaking & Trending Today

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design - Vimarsana News

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design

Published: May 21, 2024

Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.

Source: onclive.com
Related Topics:
Multicenter TrialMaintenance Therapy After SystemicPatients WithRecurrent Endometrial Carcinoma
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings - Vimarsana News

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

Published: September 26, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomSouth KoreaKyongsang BuktoHong KongReshma RangwalaKaryopharm Selective Inhibitor Of Nuclear ExportEuropean UnionInternational Myeloma SocietyInformation DepartmentKaryopharm Therapeutics IncSelective Inhibitor Of Nuclear ExportExchange CommissionEuropean Society Of Gynaecological OncologyDrug AdministrationKaryopharm TherapeuticsMyeloma SocietyAnnual MeetingBest Oral SessionEndometrial CancerGynaecological OncologyChief Medical OfficerRecurrent Endometrial CancerSpecified Subgroup AnalysisMulticenter Trial
U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia - Vimarsana News

U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Published: August 14, 2023

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical... -Today at 08:04 am- MarketScreener

Source: marketscreener.com
Related Topics:
United StatesMarkj FoleyPeter McallisterAssociation Of Academic Physiatrists Annual MeetingPeptide Exchange TechnologyRevance Therapeutics IncAmerican Academy Of Physical MedicineSecurities ExchangeDystonia Medical Research FoundationDrug AdministrationExchange CommissionEngland Institute For NeurologyHint IncViatris IncRevance TherapeuticsChief Executive Officer MarkNew England InstituteLabel StudyBoxed WarningDistant SpreadSpecific PopulationsPrescribing InformationRelational CommerceShanghai Fosun PharmaceuticalResilient Hyaluronic Acid
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting - Vimarsana News

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

Published: June 5, 2023

-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being... | June 5, 2023

Source: marketscreener.com
Related Topics:
Olmsted CountyUnited StatesJeffreyw ShermanMalini GuptaDuke University Health SystemEuropean Group On Grave OrbitopathyDrug AdministrationEndocrine SocietyHorizon TherapeuticsThyroid Eye DiseaseSafety ResultsPlacebo Controlled Multicenter TrialOral PresentationMulticenter TrialHearing Related Issues AssociatedGrave DiseaseHearing Related Adverse EventsTeprotumumab Oncology Clinical TrialsTeprotumumab Pooled EfficacyEuropean Study Sites ParticipatingInactive Thyroid Eye Disease Patient JourneyEye DiseaseEarly DiagnosisDuke University HealthTreatment Experience
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings - Vimarsana News

Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings

Published: May 23, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesKyongsang BuktoSouth KoreaUnited KingdomHong KongReshma RangwalaPrnewswire Karyopharm Therapeutics IncEuropean Hematology AssociationDrug AdministrationKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentEuropean UnionKaryopharm Therapeutics IncAmerican Society Of Clinical OncologySelective Inhibitor Of Nuclear ExportExchange CommissionClinical OncologyAnnual MeetingHematology AssociationHybrid CongressChief Medical OfficerMulticenter TrialRefractory Multiple MyelomaAntib Cell MaturationTargeting Therapy After